Home › Biliary Tract Cancer › Pennsylvania
Biliary Tract Cancer clinical trials in Pennsylvania
10 studies for Biliary Tract Cancer are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- University of Pittsburgh Medical Center (UPMC), Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05482893A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Lancaster
- Research Site, Philadelphia
- Research Site, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07221253SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07812805AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Philadelphia
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07038343A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
- UPMC, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Pittsburgh
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Aug 19, 2026 · NCT06467357A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Thomas Jefferson University, Philadelphia
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Sidney Kimmel Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07458347Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT05733598Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
- AHN West Penn Hospital, Pittsburgh
Recruiting
Ages 18 to 89 · All sexes · Updated Sep 18, 2025 · NCT06731998From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.